Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease

• Prospective, multi-center single-arm observational study Screening (day 0): 1. Medical history and demography of the patient reviewed 2. Inclusion/exclusion eligibility will be checked 3. Physical examination (Height, weight) 4. Laboratory test * BUN, eGFR, Cr. * Hb, WBC, platelet * Lipid level (total cholesterol, LDL-C, triglyceride, HDL-C) 5. Ankle-brachial index 6. Imaging study (CT/MR angiography, Doppler ultrasound, or catheter angiography) 7. Medication Enrollment (day 0): 1\) Written consent Post PTA (Day 1 \~3): 1. Adverse event 2. Ankle-brachial index 3. Laboratory test: * BUN, eGFR, Cr. * Hb, WBC, platelet 4. Concomitant medication Regular Follow-up Visits Visit 1 (post-PTA 30±14 days) 1\) Symptom: Rutherford class 2) Laboratory test: * BUN, eGFR, Cr. * Hb, WBC, platelet 3) Concomitant medication 4) Adverse event Visit 2 (post-PTA 6 months ± 30 days) 1. Symptoms: Rutherford class 2. Ankle-brachial index 3. Concomitant medication 4. Adverse event Visit 3 (post-PTA 12 months ± 60 days) <!-- --> 1. Symptoms: Rutherford class 2. Ankle-brachial index 3. Duplex ultrasound, CT, or catheter angiography 4. Biplane radiograph of femur for evaluation of stent fracture 5. Laboratory test * BUN, eGFR, Cr. * Hb, WBC, platelet * Lipid level (total cholesterol, LDL-C, triglyceride, HDL-C) 6)Concomitant medication 7) Adverse event Visit4 (post-PTA 24 months ± 60 days) 1. Symptom: Rutherford category 2. Adverse events